National Institute for Health and Care Excellence

Spectra Optia for automatic red blood cell exchange in people with sickle cell disease

The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...
Business Wire

Terumo BCT Launches Mononuclear Cell Collection Protocol for Spectra Optia® Apheresis System in the United States

LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...
Business Wire

U.S. Food and Drug Administration Clears Sickle Cell Disease Indication with New Red Blood Cell Exchange (RBCX) Protocol on the Spectra Optia ® Apheresis System in the United ...

LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for RBCX on the Spectra Optia Apheresis System. This option gives clinicians ...
PharmiWeb

Terumo Blood and Cell Technologies optimizing cell therapy production through industry’s first apheresis training for cell therapy manufacturers

Terumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia(R) Apheresis System at major conferences Lakewood, Colorado, US, May 25, 2023 – Terumo Blood and ...